Axovant Gene Therapies Ltd. (AXGT)
Stock Price:
$3.02 USD
0.05 (1.68%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $3.09 +0.07 (2.32%) Aug 7, 5:38 PM
Key Info
| Market Cap |
121.81M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-72.63M |
| Shares Out |
39.53M |
| EPS (ttm) |
-2.93 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 7, 2020 |
| Last Price |
$3.02 |
| Previous Close |
$2.97 |
| Change ($) |
0.05 |
| Change (%) |
1.68% |
| Day's Open |
2.98 |
| Day's Range |
2.98 - 3.04 |
| Day's Volume |
195,949 |
| 52-Week Range |
1.41 - 8.08 |
More Stats
| Market Cap |
121.81M |
| Enterprise Value |
57.45M |
| Earnings Date (est) |
Nov 9, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
39.53M |
| Float |
15.05M |
| EPS (basic) |
-2.93 |
| EPS (diluted) |
-2.93 |
| FCF / Share |
-2.73 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
253,583 |
| Short Ratio |
1.00 |
| Short % of Float |
1.37% |
| Beta |
1.57 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
1.95 |
| Revenue |
n/a |
| Operating Income |
-69.17M |
| Net Income |
-72.63M |
| Free Cash Flow |
-67.73M |
| Net Cash |
64.36M |
| Net Cash / Share |
1.60 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-39.96% |
| ROE |
-123.34% |
| ROIC |
-3,948.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (8)
| Buy |
6 |
| Overweight |
1 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$13.71*
(353.97% upside)
Low
8.00
Current: $3.02
High
24.00
Target: 13.71
*Average 12-month price target from 7 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|
| Revenue | - | - | - | - | - | - |
| Operating Income | -69.17 | -127 | -213 | -180 | -133 | -21.05 |
| Net Income | -72.63 | -129 | -222 | -181 | -133 | -21.05 |
| Shares Outstanding | 24.81 | 16.10 | 13.42 | 12.39 | 11.81 | 2.00 |
| Earnings Per Share | -2.93 | -8.02 | -16.51 | -14.56 | -11.28 | -10.56 |
| Operating Cash Flow | -67.47 | -134 | -190 | -112 | -53.35 | -0.68 |
| Capital Expenditures | -0.26 | -0.20 | -4.28 | -0.11 | -0.09 | -0.01 |
| Free Cash Flow | -67.73 | -134 | -195 | -112 | -53.44 | -0.69 |
| Cash & Equivalents | 80.75 | 107 | 154 | 213 | 276 | 0.00 |
| Total Debt | 16.39 | 44.18 | 52.68 | 51.44 | - | - |
| Net Cash / Debt | 64.36 | 62.82 | 102 | 161 | 276 | 0.00 |
| Assets | 93.68 | 123 | 161 | 223 | 282 | 1.12 |
| Liabilities | 32.12 | 66.49 | 89.50 | 97.70 | 15.76 | 8.87 |
| Book Value | 61.56 | 56.21 | 71.29 | 125 | 267 | -7.75 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Axovant Gene Therapies Ltd. |
| Country |
United Kingdom |
| Employees |
38 |
| CEO |
Pavan Cheruvu |
Stock Information
| Ticker Symbol |
AXGT |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: AXGT |
Description
Axovant Gene Therapies Ltd., a clinical-stage company, develops gene therapies for neurodegenerative diseases. The company's product pipeline includes AXO-Lenti-PD program, an in vivo lentiviral gene therapy for the treatment of Parkinson's disease, which is in Phase II clinical trials; the AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis is in Phase I/II clinical trials; and the AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis that is in Phase I/II clinical trials. It has a license agreement with Oxford BioMedica (UK) Ltd.; license and collaboration agreement with Benitec Biopharma Limited; exclusive license agreement with The University of Massachusetts Medical School; and collaboration agreement with Invitae Corporation. The company was formerly known as Axovant Sciences Ltd. The company was founded in 2014 and is based in London, the United Kingdom.